Find Clinical Trial

Clinical long-term effects of Valdoxan® (25 or 50 mg) in depressed patients. Clinical, national, interventional, phase IV, multicentre, open study. Valdoxan® D-EXTENSION Study


← Back
Study Phase

Phase 4

Therapeutic Area

Neuropsychiatric Diseases

Active substance/
Medical device

S020098, AGOMELATINE

SponsorEUTHERAPIE / Les Laboratoires Servier
Active Substance CodeS020098
Protocol CodeDM4-20098-112
EudraCT Code2009-010112-15


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility